SRR25617869
— · F
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- F
- subtype
- F
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANDROGEN_RESPONSE+0.390
- CHOLESTEROL_HOMEOSTASIS+0.390
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.370
- UV_RESPONSE_DN+0.340
- NOTCH_SIGNALING+0.320
- PI3K_AKT_MTOR_SIGNALING+0.270
- PROTEIN_SECRETION+0.260
- APICAL_JUNCTION+0.240
- TGF_BETA_SIGNALING+0.240
- FATTY_ACID_METABOLISM+0.230
Top 10 suppressed
- MYC_TARGETS_V2-0.330
- MYC_TARGETS_V1-0.300
- G2M_CHECKPOINT-0.280
- E2F_TARGETS-0.270
- INTERFERON_ALPHA_RESPONSE-0.270
- DNA_REPAIR-0.240
- KRAS_SIGNALING_DN-0.190
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.180
- ESTROGEN_RESPONSE_LATE-0.150
- ESTROGEN_RESPONSE_EARLY-0.140
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-BH-A0B7-01A-12R-A115-07 | — | C | 0.796 |
| 2 | TCGA-C8-A12Q-01A-11R-A115-07 | — | C | 0.787 |
| 3 | TCGA-BH-A0DX-01A-11R-A115-07 | — | A | 0.787 |
| 4 | TCGA-E2-A152-01A-11R-A12D-07 | — | C | 0.781 |
| 5 | c2ccc6b3-34d8-47c5-9367-cc53aad1622e | — | — | 0.776 |
| 6 | SRR12475109 | — | — | 0.775 |
| 7 | SRR8613813 | — | D | 0.769 |
| 8 | TCGA-BH-A0BR-01A-21R-A115-07 | — | C | 0.769 |
| 9 | TCGA-BH-A208-01A-11R-A157-07 | — | A | 0.759 |
| 10 | TCGA-AO-A0JF-01A-11R-A056-07 | — | A | 0.759 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 34 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANDROGEN_RESPONSE | 0.390 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.390 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.370 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.340 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.320 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.270 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.260 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.240 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.240 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.230 | Inavolisib | — uncovered |
| COAGULATION | 0.220 | Binimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.220 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.210 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.210 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.190 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.190 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.190 | Cobimetinib | — uncovered |
| BILE_ACID_METABOLISM | 0.180 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.180 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.170 | Inavolisib | — uncovered |